Healthcare refers to the field associated with maintaining or restoring patients’ health. These days’ Healthcare Industry falls into a lashing of discrete sub-sectors, and ancillary goods and services. Ranging from therapeutic equipment to medicinal drugs, medical tourism to sickness insurance, the Healthcare Market has been one of the most swiftly expanding sectors within the globe’s economic system.
Global Healthcare spending contributes close to 10% to the whole world’s GDP, though it varies noticeably with geography. Thus, the Western world’s average healthcare costs are far greater in contrast to those in the developing economies. North America alone is in charge of circa a half of the world’s overall spending on healthcare services. With budgets curtailments and growing costs, technology advances are increasingly taking a new meaning in the global Healthcare universe.
The research reports offer comprehensive insights into the market sizing, structure and dynamics of the Healthcare Industry based on various geographies, as well as in-depth market segmentation. The research reports incorporated in this Catalogue closely investigate the competition in the Healthcare Market, besides profiling countless market participants. Moreover, tomorrow's healthcare-related challenges are addressed, as well as projections into the future are provided in the research reports.
Publications found:
113,889
Sort by:
Home Health Care Services: Market Research Report
US$ 1,995.00
The global outlook series on Home Health Care Services provides a collection of statistical findings, market briefs, and concise summaries of research findings. Amply illustrated with 24 market data, tables, charts, and graphs, the report offers a rudimentary overview of the industry, highlights latest ...
December 2011
102 pages
Oxygen Therapy: Market Research Report
US$ 1,995.00
... anecdotes, market briefs, and concise summaries of research findings. The report offers an aerial view of the global oxygen therapy industry, identifies major short to medium term market challenges, and growth drivers. Regional markets elaborated upon include United States ...
December 2011
70 pages
Health Spas: Market Research Report
US$ 1,995.00
The global outlook series on Health Spas provides a collection of statistical findings, market briefs, and concise summaries of research findings. Market discussions in the report are amply illustrated with 57 fact-rich market data tables, charts, and graphs. Regions covered include United States, ...
December 2011
112 pages
Alternative Medicine: Market Research Report
US$ 1,995.00
The global outlook series on the Alternative Medicine Industry provides a collection of statistical anecdotes, market briefs, and concise summaries of research findings. Illustrated with 31 fact-rich market data tables, the report offers a rudimentary overview of the industry, and highlights latest trends ...
December 2011
148 pages
Emergency and Other Relief Services: Market Research Report
US$ 1,995.00
The global outlook series on Emergency and Other Relief Services provides a collection of statistical anecdotes, market briefs, and concise summaries of research ... , Canada, Japan, Australia, China, India and New Zealand, among others. Also included is an indexed, easy-to-refer, fact-finder directory listing ...
December 2011
70 pages
Healthcare Services: Market Research Report
US$ 1,450.00
The global outlook series on Healthcare Services provides a collection of statistical anecdotes, market briefs, and concise summaries of research findings. The report details the prevailing situation in the world healthcare delivery system, and provides extensive coverage of all the recent mergers, and ...
December 2011
94 pages
46 Healthcare Metrics to Boost Profitability: Charting 2013 Trends
US$ 127.00
... the healthcare C-suite that distills emerging trends into easy-to-digest charts and tables. THIS ALL-NEW 2013 EDITION provides program ... , diabetes management and asthma management. View the preview of '46 Healthcare Metrics to Boost Profitability: Charting 2013 Trends.' This 70-page desktop resource is ...
December 2011
Digital Health Quarterly 1Q 2012 2Q 2012
US$ 1,500.00
The Market Tracker: Digital Health Quarterly offers in-depth analysis of the latest corporate news, industry events, passed and pending legislation, and government directives related to the digital health industry.
December 2011
16 pages
Digital Health Quarterly 2Q 2012 3Q 2012
US$ 1,500.00
The Market Tracker: Digital Health Quarterly offers in-depth analysis of the latest corporate news, industry events, passed and pending legislation, and government directives related to the digital health industry.
December 2011
16 pages
Digital Health Quarterly 3Q 2012 4Q 2012
US$ 1,500.00
The Market Tracker: Digital Health Quarterly offers in-depth analysis of the latest corporate news, industry events, passed and pending legislation, and government directives related to the digital health industry.
December 2011
18 pages
Digital Health Quarterly 4Q 2011 1Q 2012
US$ 1,500.00
The Market Tracker: Digital Health Quarterly offers in-depth analysis of the latest corporate news, industry events, passed and pending legislation, and government directives related to the digital health industry.
December 2011
17 pages
Health Entertainment: Bringing the Fun to Wellness and Fitness 3Q 2012
US$ 3,500.00
This report analyzes the intersection of the entertainment world with human health and well being. It defines this unique industry sector with ... -user revenues. "Health entertainment is a perfect example of technology’s imprint on the science of human behavioral changes," said Harry Wang, Director of Mobile & Health Research at Parks ...
December 2011
55 pages
Para IV pluse Subscriptions
US$ 4,500.00
Para IV Plus is a knowledge bank of ongoing pharma patent litigations covered in the most comprehensive manner. Currently it covers ~400 product patent litigations – i.e. ALL the patent litigations involving global as well as non global innovator companies.
December 2011
Global HIV Therapeutics Market Analysis
US$ 1,200.00
HIV endemic has had devastating economic, social, health and psychological impacts over the years affecting millions of households in a significant manner over the last decade. Despite the concrete ef...
December 2011
70 pages
Global Regenerative Medicine Market
US$ 1,200.00
Regenerative medicine is an emerging interdisciplinary field that spans tissue engineering, stem-cell biology, nanoscience, and bioengineering for the repair of cells, tissues and organs. It seeks to...
December 2011
105 pages
US Healthcare Market Outlook 2013
US$ 1,000.00
The US represents the world’s largest healthcare market, with a high annual healthcare spending. The growth in healthcare spending is mainly driven by high administrative costs, and expensive hospital...
December 2011
80 pages
Kraft Foods inc in Health and Wellness (World)
US$ 572.00
... the wake of the Cadbury acquisition, Kraft Foods nearly doubled its global health and wellness (HW) sales to US$16.5 billion in ... its portfolio development with key wellness trends. Euromonitor International’s Kraft Foods Inc in Health and Wellness (World) Company Profile offers detailed strategic ...
December 2011
49 pages
Outlook 2012 - Rising Stars - Innovators Deliver but Rewards Not Guranteed!
US$ 2,000.00
... continue to flow from the backyards of small research focused companies (Rising stars, RS) but commercial success of launched products is not assured despite patents ... Micromet (MITI) are our Top Picks for FY2012 in the Rising Stars Sector. Key drugs of ANTH and MITI target high unmet ...
December 2011
52 pages
Competitor Analysis: HIV Small Molecule Therapeutics
US$ 642.00
The present Competitive Intelligence report about HIV Small Molecule Therapeutics used to treat human immunodeficiency virus (HIV) infections provides a competitor evaluation in the field of marketed...
December 2011
100 pages
NOVARTIS - Tekturna: ALTITUDE study in high risk hypertensive patients TERMINATED
US$ 90.00
... the termination of large PhIII study (ALTITUDE) due to higher rate of adverse events and no benefits observed for patients taking Tekturna in addition to ACE ... inhibitors. Post this announcement, NVS will cease promotion of Tekturna/Tekturna products in combination with ACE inhibitors/ARB inhibitors. The event ...
December 2011
1 pages
LUPIN - Lupin - Loss of 2 Exclusivities Further Exposes the weak Pipeline
US$ 140.00
... . Most glaring is the Fortmet case, where Lupin launched the product ‘at-risk’ and later withdrew ... settled with Lupin it cannot launch its generic version (unless ‘at-risk’) thereby leading to a loss of this ... shared 180-day exclusivity for Lupin. These add to the pressure ...
December 2011
3 pages
MSL-KOL Engagement: Measuring Success
US$ 595.00
It’s difficult to quantify. Its role constantly changes. And despite all efforts to gain transparency, the field of medical science liaison (MSL) remains an elusive—seemingly immeasurable—yet undeniab...
November 2011
26 pages
US Glucose Monitoring Market Analysis
US$ 1,000.00
The US has a dominant share in the global diabetes market with 90-95% of the diabetic patients in the country suffering from type-II diabetes. Factors like, high prevalence of diabetes, rising aging p...
November 2011
55 pages
World Market for Prescription Arthritis Treatments
US$ 3,500.00
... management. This Kalorama Information report, The World Market for Prescription Arthritis Treatments, details the market for these treatments. The report provides ... There are several issues and trends that are shaping this market. Some of the topics, discussed in this report include: US Economic Impact ...
November 2011
150 pages
Competitor Analysis: Anti-Infective Antibodies
US$ 1,086.00
Product description The present Competitive Intelligence Report about Anti-Infective Antibodies provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies and human plasma-derived immunoglobulins and hyperimmunes for post-exposure prophylaxis and treatment of ...
November 2011
160 pages
GALAPAGOS - Waiting for Santa!
US$ 90.00
... , please read our report released on 22nd November on GLPG titled “Waiting for Santa”!
November 2011
3 pages
PHARMASSET - "IFN-free Oral Option" for HCV- Sharing the Big Pie!
US$ 140.00
Pharmasset (VRUS) may enjoy the first mover advantage in the race to offer the first “IFN free all oral option” to HCV pts. However the window ... read our report released on Nov. 16th, 2011 on VRUS titled “IFN-free Oral Option” for HCV- Sharing the Big Pie!
November 2011
9 pages
SUN PHARMA - A structural improvement at play
US$ 140.00
Sun’s Q2 FY12 result was much higher than our and street’s ... after acquisition of 100% stake. We thus rate Sun Pharma as our top pick in the large cap India pharma. We will change our estimate later to incorporate ...
November 2011
7 pages
Lemtrada: Co-primary Endpoints Met in CARE MS II: Ready for filing
US$ 90.00
... alert on Sanofi, after today’s announcement of superior clinical data on Lemtrada from CARE MS II (The Comparison of Alemtuzumab and Rebif Efficacy in ... Sclerosis) study. A cross trial comparisons (Table 1) suggest that Lemtrada should dominate as the most efficacious treatment option, and Ocrelizumab ...
November 2011
4 pages
CADILA HEALTHCARE - Still Carrying The Burden of The High Base Last Year
US$ 140.00
Cadila’s Q2 FY12 result was below our estimate (adjusted to ... for muted growth in markets like India and Emerging Markets, we believe that the growth is still impacted due to the high ... the markets. We thus do not see any structural issues with Cadila. In addition, USFDA approval of its Baddi facility comes as a ...
November 2011
5 pages
DISHMAN - Downward Guidance Revision – No More An Exception
US$ 140.00
Dishman once again reported quarterly result much below our and ... . Thus debt repayment can happened only through asset sale. We revise our FY 12 earnings estimates down by 28%. Consequently we cut our target price ...
November 2011
5 pages
RANBAXY - Moderate Improvement In Base Business
US$ 140.00
We reiterate our Market Perform rating on Ranbaxy after Q3 CY11 result that was largely in line with our ... the low base of EBITDA margin, the improvement was expected to be slightly higher especially as Ranbaxy has shut down most of its loss making ...
November 2011
6 pages
LUPIN - Margin Pressure Highlight The Weakness of US Portfolio
US$ 140.00
... on Lupin after its Q2FY12 result that was largely in line with our estimates. Ex-Medicis milestone income, sales growth (up 17%) and gross margin ... of one per quarter and (3) Suprax growing by 43% Y-o-Y. We believe all these highlights (1) the dependence on generic Lotrel (2) increased sales force expense for ...
November 2011
6 pages
TOWA - Performance Will Outcast New ‘Mid Term Plan’
US$ 140.00
In Towa’s MTP announcement, it has projected single digit revenue growth and assumed there will not be any ‘New Major Reform’ by Govt to enhance ... in dispensing fee and incentives to doctors will boost Towa’s revenue (as 90%+ its revenue from these two segments), 2) Towa management is taking the right decision ...
November 2011
7 pages
Interacting with KOLs: Fulfilling Current Unmet Needs
US$ 995.00
The symbiotic relationship between key opinion leaders (KOLs) and the pharmaceutical industry is dynamic and ever-changing. But while the industry knows what it wants from KOLs, what do KOLs need from...
October 2011
41 pages
PHARMASSET - 'IFN-Free Oral Option' for HCV - Not a Virgin Territory Anymore!
US$ 90.00
... ) wave to treat HCV the race to offer the first “IFN free all oral option” seems to have begun. Preliminary data from Abbott’s PhII trial ... ’11 is challenging Pharmasset (VRUS) multiprong approach. For more details, please read our report released on Oct. 24th, 2011 on VRUS titled “IFN-free Oral Option” for ...
October 2011
4 pages
